Drug Development Infrastructure Supporting the Research Community in Medication Repurposing for Substance Use Disorders
National Institutes of Health
✓Data quality: Source-backedSeen at source 4d agoVerified source
Published
Deadline
Coverage
United States
The National Institute on Drug Abuse (NIDA) seeks to advance its mission by supporting a dynamic and adaptable drug-development infrastructure to accelerate medication repurposing and repositioning for substance use disorders (SUDs). The infrastructure will serve academic and biotech investigators by providing coordinated scientific expertise, shared resources, and tailored support across the drug-development continuum. Capabilities may include in silico discovery, target and assay validation, preclinical and translational development, pharmacology, toxicology, clinical protocol development, patient engagement, Target Product Profile development, Freedom-to-Operate and intellectual property strategy, regulatory guidance, and market-access planning. The infrastructure will also engage the research community through outreach, proposal solicitation, and a structured project-selection process, supporting user-led projects across a broad range of SUD indications. The goal is to help promising repurposed and repositioned therapeutics progress toward clinical development and potential market access. Grant authorities that allow the NIDA to forecast this opportunity are as follows: 42 U.S.C. 241 and 284.
The National Institute on Drug Abuse (NIDA) seeks to advance its mission by supporting a dynamic and adaptable drug-development infrastructure to accelerate medication repurposing and repositioning for substance use disorders (SUDs). The infrastructure will serve academic and biotech investigators by providing coordinated scientific expertise, shared resources, and tailored support across the drug-development continuum. Capabilities may include in silico discovery, target and assay validation, preclinical and translational development, pharmacology, toxicology, clinical protocol development, patient engagement, Target Product Profile development, Freedom-to-Operate and intellectual property strategy, regulatory guidance, and market-access planning. The infrastructure will also engage the research community through outreach, proposal solicitation, and a structured project-selection process, supporting user-led projects across a broad range of SUD indications. The goal is to help promising repurposed and repositioned therapeutics progress toward clinical development and potential market access. Grant authorities that allow the NIDA to forecast this opportunity are as follows: 42 U.S.C. 241 and 284.
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
NIDA OTIPI Program StaffPlease contact via e-mail.
The notice above is the public record. Signing in adds the analysis: saved views and alerts on searches like this one, workflow and pipeline, exports and full workspace tooling.